Novo Nordisk has agreed to evaluate a GLP-1 implant developed by biopharmaceutical company Vivani Medical.
The implant, called NPM-139, delivers semaglutide through a titanium reservoir fitted with a membrane containing microscopic channels designed to release the drug at a steady rate over several months, according to a July 7 news release.
Vivani is targeting the adherence problem that has dogged GLP-1s since their rise. More than half of patients discontinue GLP-1 therapy within the first year, and older adults quit at even higher rates, with cost and lack of Medicare coverage for weight-loss use cited as key drivers. The implant is envisioned as a maintenance option rather than a starting therapy: patients would first reach a stable dose using existing injections or pills, then could switch to an implant calibrated to match that dosage, administered twice a year or eventually once a year, according to a July 11 report by CNBC.
The phase 1 study is expected to begin in mid-2026 and will enroll about 20 overweight or obese adults who have not previously taken GLP-1s, randomizing them to the implant or a low-dose weekly Wegovy injection over four weeks to assess safety, tolerability and pharmacokinetics, according to the news release.
However, physicians were cautiously skeptical, according to CNBC. Miranda Stiewig-Rapp, MD, from Sacramento-based University of California Davis Health’s Obesity Clinic said she wants to see long-term tolerability data before drawing conclusions. Amy Rothberg, MD, from the University of Michigan in Ann-Arbor called the implant a reasonable option but said the insertion procedure could require significant provider training and add costs for insurers, noting adoption of a similarly implanted continuous glucose monitor has been limited.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
